A phase II trial of 5-fluorouracil, folinic acid, vinorelbine in pretreated patients with metastatic colorectal cancer

R. V. Iaffaioli, G. Facchini, A. Tortoriello, F. Caponigro, G. Gesue, A. Finizio, N. Di Martino, G. De Sena, B. Antonelli, G. Scaramellino, L. Fei, M. Santangelo, L. Bucci

Research output: Contribution to journalArticle

Abstract

43 patients with metastatic colorectal cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.

Original languageEnglish
Pages (from-to)513-516
Number of pages4
JournalOncology Reports
Volume2
Issue number4
Publication statusPublished - 1995

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Colorectal cancer
  • Folinic acid
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A phase II trial of 5-fluorouracil, folinic acid, vinorelbine in pretreated patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Iaffaioli, R. V., Facchini, G., Tortoriello, A., Caponigro, F., Gesue, G., Finizio, A., Di Martino, N., De Sena, G., Antonelli, B., Scaramellino, G., Fei, L., Santangelo, M., & Bucci, L. (1995). A phase II trial of 5-fluorouracil, folinic acid, vinorelbine in pretreated patients with metastatic colorectal cancer. Oncology Reports, 2(4), 513-516.